Yu Fan Invests $31.63 Million in CeriBell (NASDAQ:CBLL)

Yu Fan acquired a new position in shares of CeriBell (NASDAQ:CBLL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,222,202 shares of the company’s stock, valued at approximately $31,631,000. CeriBell comprises about 55.8% of Yu Fan’s investment portfolio, making the stock its biggest position. Yu Fan owned about 3.41% of CeriBell as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CBLL. Legal & General Group Plc acquired a new position in CeriBell in the fourth quarter valued at $32,000. Summit Investment Advisors Inc. acquired a new position in CeriBell in the fourth quarter valued at $33,000. Tower Research Capital LLC TRC acquired a new position in CeriBell in the fourth quarter valued at $37,000. BNP Paribas Financial Markets acquired a new position in CeriBell in the fourth quarter valued at $43,000. Finally, PNC Financial Services Group Inc. acquired a new position in CeriBell in the fourth quarter valued at $47,000.

CeriBell Stock Down 0.8%

Shares of NASDAQ CBLL opened at $17.83 on Tuesday. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The stock’s 50-day simple moving average is $17.43 and its 200-day simple moving average is $22.32.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analysts’ expectations of $19.30 million. Research analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on CBLL shares. Canaccord Genuity Group reissued a “buy” rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday, April 4th. They issued a “buy” rating and a $32.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.50.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 3,372 shares of CeriBell stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16. Following the sale, the chief executive officer now directly owns 743,079 shares of the company’s stock, valued at approximately $11,168,477.37. The trade was a 0.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is currently owned by insiders.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.